Navigation Links
Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
Date:10/13/2009

CINCINNATI, Oct. 13 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) announced today that it will release its third quarter 2009 financial results after the market closes on Wednesday, Nov. 4, 2009. The Company will host a telephone conference call and simultaneous webcast on Thursday, Nov. 5 at 8:30 a.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (866) 834-5752. Participants outside North America should dial (706) 643-4051. A replay will be available through 5 p.m. Eastern Time on Dec. 4, 2009 by dialing (706) 645-9291 and entering conference ID number 34948043.

Webcast Instructions

To access the live webcast, visit the company Web site at www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=62837. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Dec. 4, 2009. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

SOURCE Kendle International Inc.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... April 27, 2016 Transparency Market ... Devices Market - Global Industry Analysis, Size, Share, Growth, ... report, the global skincare devices market was valued at ... expand at a CAGR of 10.1% from 2015 to ... Browse the full Skincare Devices Market (Treatment Device - ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery community, ... forum section was recently revamped and upgraded to allow even more interaction between doctors ... the country. , According to the senior editor of Cosmetic Town, “We are excited ...
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon ... collaborating with doctors and hospitals to make transformative changes in how health care ... therapy minds this week in discussing breakthroughs in cellular medicine to treat disease. ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her ... again much like a tsunami and took on a more spiritual tone. The desire to ... to do more with it than just file it away. Friends would ask her how ...
Breaking Medicine News(10 mins):